4.8 Article

Oral pyroptosis nanoinhibitor for the treatment of inflammatory bowel disease

Journal

NANO RESEARCH
Volume -, Issue -, Pages -

Publisher

TSINGHUA UNIV PRESS
DOI: 10.1007/s12274-023-5969-3

Keywords

inflammatory bowel disease; nanoinhibitors; pyroptosis; synergistic therapy; antioxidant

Ask authors/readers for more resources

In this study, an oral nanoinhibitor was designed to target intestinal lesions and release active sites and drugs in response to reactive oxygen species (ROS), thereby reducing inflammation and improving intestinal barrier function. It also decreased inflammatory cytokine levels and increased gut microbiota diversity in mice with colitis.
Inflammatory bowel disease (IBD) is an autoimmune gastrointestinal disease characterized by chronic relapsing inflammation of the intestine. Excessive pyroptosis that exists in the inflamed intestine can activate damage signals and aggravate local inflammation in IBD. Here, we designed an oral pyroptosis nanoinhibitor, DXMS@CuM@PPADT@PSS (DCMP), which can target intestinal lesions, and respond to reactive oxygen species (ROS) to release active sites and drugs at the lesion. DCMP can inhibit the activation of the nucleotide-binding domain and leucine-rich repeat family pyrin domain containing 3 (NLRP3) inflammasomes by scavenging ROS, resulting in the down-regulation of gasdermin D (GSDMD) cleavage thus inhibiting pyroptosis. It also improved intestinal barrier function, decreased inflammatory cytokine levels, and increased the diversity of gut microbiota in mice with colitis. This work is believed to expand the biomedical application of nanomaterials for innate immunity modulation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available